Fort Dodge Animal Health has announced that its Duvaxyn WNV vaccine against West Nile Virus (WNV) is now available in the UK, following its licensing through the European Medicines Agency (EMEA).
Duvaxyn WNV is the first vaccine available in Europe to protect horses against this emerging disease threat. 288 horses and two people in Italy were found to be infected with WNV during the outbreak that hit northern Italy in late 2008 where it is now considered endemic. The disease is endemic in all areas of North America where it has claimed the lives of both horses and humans.
West Nile Virus is caused by a highly contagious flavivirus, which is transmitted by mosquitoes, primarily of the Culex species. The natural hosts of West Nile virus are birds, with migratory birds from Africa carrying the disease. Mosquitoes become infected after taking a blood meal from infected birds and then may transmit the disease to horses and even humans. While horses are 'dead end hosts,' the consequences can be severe as the virus causes encephalitis or meningitis. Mortality rates among horses which develop neurological signs are high and there is no palliative cure for the disease. Treatment is limited to symptomatic relief which can be long and expensive.
Sabrina Jordan, UK Business Manager for Equine Vaccines at Fort Dodge said: "WNV is an increasing threat to the equestrian sector in the UK and is a particular challenge for owners who transport their horses around the world.
"The fact that a vaccine is now available will undoubtedly offer peace of mind to the equestrian community. They can be reassured that horses in the UK can now be vaccinated against WNV with a vaccine that has already been shown to be highly effective in protecting horses in America.
"With any vaccine, a record that a horse has been vaccinated with Duvaxyn WNV should be recorded in its horse passport. By presenting this vaccine in pre-filled syringes with Infovax-ID labels, we've aimed to make both the administration and record keeping of Duvaxyn WNV as convenient as possible.
"To build understanding of this potentially fatal disease threat, we are continuing to work with governments and authorities at a national and European level, as well as working in partnership with the UK's veterinary community to ensure that owners are fully informed about the risk WNV poses and of the benefits of vaccination."
The Veterinary Wound Healing Association (VWHA) has become the third veterinary association to make a new home on VetSurgeon.org.
VWHA President Jacintha Wilmink said: "We're very excited about joining VetSurgeon.org and how it will allow our members to connect with each other and share information quicker and more easily than ever before".
In common with the other associations, the VWHA is making its content available for all VetSurgeon members to access, however only VWHA members can submit cases to its section for discussion, or participate in the VWHA forum. Jacintha added: "We hope that the cases and discussions in our section of the site will be of value to all practitioners, and that many more of you will want to join the association and participate".
Information about the benefits of joining the VWHA is available here.
"Advances in Imaging of the Equine Distal Limb 2017–2022" comprises a total of 20 papers which have been selected by Mathieu Spriet, Ann Carstens and Tim Mair.
It also includes an editorial from the EVJ summarising the major historical technological developments in imaging of the foot and fetlock.
The publication looks at the evolution of computed tomography (CT), positron emission tomography (PET), which has opened a whole new field of possibilities for bone and soft tissue imaging in racehorses and sport horses, MRI and how it has been improved by optimising scanning techniques, ultrasound radiography and scintigraphy.
Mathieu Spriet said: “The content of this virtual issue represents an amazing amount of new knowledge that with no doubt will contribute to improve equine welfare and safety.
“With the increase availability and versatility of all the imaging modalities, the knowledge base appears to increase exponentially.
"We are very excited to see what the next five years will bring. We hope the readers will enjoy consulting this collection as much as we enjoyed putting it together.”
The virtual issue is free for 12 weeks and can be found at https://beva.onlinelibrary.wiley.com/doi/toc/10.1001/(ISSN)2042-3306.equine-distal-limb
Photo: 18F-NaF PET, CT and MRI images from a horse with navicular and middle phalanx lesions. Adapted from EVJ 2018;50: 125-132
He takes over the role from Huw Griffiths at the end of BEVA Congress 7th -10th September 2022. Roger Smith becomes President Elect.
Following graduation from The University of Bristol in 2001, David worked in farm animal and equine practice in Somerset before completing an internship at Liphook Equine Hospital.
A three-year Horserace Betting Levy Board residency at The University of Glasgow and Liphook Equine Hospital enabled him to train as a specialist in equine internal medicine and to gain a masters by research into equine asthma and an RCVS certificate in equine medicine.
David spent several years at Liphook Equine Hospital in Hampshire and had spells at The Royal Veterinary College, London and Charles Sturt University in Australia before moving to Rainbow Equine Hospital in Yorkshire where he led the internal medicine and laboratory services as a director and subsequently a clinical director following the hospital’s acquisition by the VetPartners group.
David returned to his Westcountry roots in 2020 and now combines work as an independent equine medicine and therapeutics consultant with running the family farm on the edge of Exmoor.
He is chair of BEVA’s health and medicines committee.
During his presidential year David is keen to continue build on his recent work around antimicrobial and anthelmintic resistance as well as expanding BEVA’s global outreach to support more equine vets and have a greater impact on equine welfare.
He said: “I’ve had a great time being part of the profession for the past 20 years and I am now in a position to give something back.
“Huw has driven much activity in the past year around recruitment and retention and I hope to be able to build on this and action results from the recent survey, under Huw’s continued supervision. I am also determined to maintain momentum around BEVA’s antimicrobial and anthelmintic resistance work as well as step up collaboration internationally on these and other projects to extend BEVA’s global outreach.
“Around 99% of the world’s horses are cared for by around 1% of the world’s vets so we are not going to change things overnight; however, BEVA has so much to offer and we should use our resources to support equine welfare, irrespective of where equine vets and their patients live and work.”
The webinars will take place every Wednesday at 7pm in May.
David Bardell is a European and Royal College of Veterinary Surgeons Specialist in Veterinary Anaesthesia and Analgesia and will be hosting the first two sessions covering equine pain management for colic and orthopaedic cases respectively.
The 5th May webinar will cover how to recognise and understand the pathology of visceral pain, physical and pharmacological methods of analgesia and dealing with violent or difficult colic cases.
The second webinar on the following Wednesday, will look at how to recognise and quantify pain, the use of pain scales, analgesic medication and techniques.
The other two sessions of the series will be led by Dr. Andy Fiske-Jackson, Deputy Head of RVC Equine and Senior Lecturer in Equine Surgery at the Royal Veterinary College. He'll be running case-based sessions looking at the good, bad and ugly of digital flexor tendon sheath cases and unravelling the diagnosis and treatment of navicular syndrome, the associated biomechanics and treatment options respectively.
Emma Jennings, Equine Brand Manager at Dechra (pictured right) said: “The broad scope of illnesses and conditions facing those specialising in equine care means that it’s important to delve deeper into some key issues, which is what this series of webinars will do.
“We hope the expertise of David Bardell and Dr. Andy Fiske-Jackson will be of key interest to veterinary professionals across the country and would urge anyone interested to register for the sessions throughout May.”
To register for the free webinars, visit www.dechra.co.uk/events.
The current inventory of Equip Artervac has an expiry date of March 29, 2023 and the company is not expecting a new batch to be available until the end of September 2023.
Zoetis says it has been working with relevant organisations to implement a plan to mitigate the impact on breeders.
The Thoroughbred Breeders Association has published advice for a blood sampling scheme at: https://www.rossdales.com/news-events/tba-members-equine-vaccine-advice-regarding-disruption-to-supply-of-equip-artervac, but Zoetis highlights that the advice requires action two weeks after the most recent EVA vaccination.
For more information contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0345 300 8034
The 'Vet REACT Colic Champions', which is being supported by 62 veterinary practices around the country, will help horse owners create a plan of action if their horse develops critical colic and needs referral to an equine hospital.
The campaign follows research conducted by the University of Nottingham which found that one in three emergency call-outs by vets were due to colic and 90% of owners were not confident in spotting its early signs.
Emmeline Hannelly, Welfare Education Manager at the BHS said: "It’s fantastic that so many vets are supporting our 'Vet REACT Colic Champions' scheme – we are delighted to be working with them. We hope that it will help even more owners to make informed decisions related to colic and in turn, improve equine welfare.”
Sarah Freeman, Professor of Veterinary Surgery at the School of Veterinary Science and Medicine, University of Nottingham said: "We are delighted to be working with vet practices on the 'Vet REACT Colic Champions' scheme. Their support and guidance has been a huge help in reaching such a wide population and we hope we can reach even more people in the future."
Alex Kingdon, BVM BVS MRCVS from Avonvale Equine Practice said: "Being part of the 'Vet REACT Colic Champions' scheme is incredibly important to our practice. Colic is by far one of the most common emergency conditions we see and the scheme has already had a huge impact on many horse owners.”
For further details on the 'Vet REACT Colic Champions' scheme and 'React Now to Beat Colic' campaign, visit: www.bhs.org.uk/colic
Photo: Shutterstock/PJ Photography
A team of researchers led by Tim Mair, CVS Equine Veterinary Director and Specialist in both Equine Internal Medicine and Equine Soft Tissue Surgery at Bell Equine Veterinary Clinic, will review 100 cases of colitis in adult horses and 100 controls referred to seven equine veterinary hospitals in the UK: five CVS equine veterinary hospitals as well as Rossdales Equine Hospital and University of Liverpool’s equine hospital.
A set of diagnostic tests on blood and faeces will be performed in these cases.
The laboratory tests will include: small redworm serology, culture and PCR of faeces for Salmonella spp, PCR of faeces for Clostridioides difficile and Clostridium perfringens, ELISA of faeces for toxins of C.difficile and C.perfringens, PCR of faeces for coronavirus.
The clinical features, laboratory results, treatments and outcomes will also be recorded.
Tim said: “Acute colitis accounts for around 5% of admissions to referral hospitals.
"And of those who are referred with it, half will not survive but there is very limited evidence available.
"So it’s vital that we build our evidence-base of this life-threatening condition.
"We hope that the outcomes of our new study will lead to a greater understanding of the causes and better inform veterinary treatment of colitis in UK adult horses.”
The Colitis in Adult Horses study is supported by a research grant from CVS, and funding for the small redworm ELISA will be given from Austin Davis Biologics.
The study started at the beginning of 2024 and the first horses have been recruited.
The results of the study are expected to be published in 2025.
Elanco has announced the results of a challenge study which the company says demonstrates the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course1.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
According to Elanco, this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade2.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of this challenge study provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE have identified as being of concern."
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. Elanco says that experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly-based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine3.
References:
The Disciplinary Committee of the RCVS has approved an application for restoration to the Register from an Oxfordshire veterinary surgeon who had been struck off for false certification.
In November 2007, the Committee decided that Mr John Williams, of the Avonvale Veterinary Practice in Ratley, near Banbury, should have his name removed from the RCVS Register, having found him guilty of disgraceful professional conduct. Mr Williams had admitted signing export health certificates for three horses in October 2006 to state that they had received negative test results for the contagious equine metritis organism, before these results were actually available.
At the time, Mr Williams was working in his capacity as an Official Veterinarian (OV) for DEFRA and he had previously been suspended from his official duties on three separate occasions, on the basis of export certification irregularities. It was accepted that Mr Williams had not been dishonest, but his approach to certification was described by the Disciplinary Committee as "either irresponsible or cavalier or both".
In December 2007, Mr Williams appealed against this decision to the Privy Council but this was dismissed at a Hearing the following June. He was then removed from the Register in July 2008.
When the Committee met on Monday to consider Mr Williams' application, they heard oral and written supporting evidence from veterinary surgeons and equine clients, and oral evidence from Mr Williams himself. The Committee was satisfied that Mr Williams accepted its previous findings and fully understood their seriousness. He described his removal from the Register as a "salutary experience" which had been highly significant for him and his family, both financially and emotionally.
The Committee stated: "Although the decision of the Committee to remove [Mr Williams] from the Register sent a clear message to the profession of the importance of certification, it should be emphasised that his removal was the consequence of his actions in signing certificates which he could not verify. This followed three previous occasions on which he had similarly signed certificates when he should not have done so."
However, the Committee was satisfied that Mr Williams would not in future sign certificates when he should not do so, even under severe client pressure. It was impressed with the continuing professional development he had undertaken whilst off the Register and noted that no questions had been raised over his conduct during this time.
It concluded that Mr Williams fully understood the importance of accurate certification and that restoring his name to the Register therefore posed no risk to animal welfare. Neither the public nor the profession would benefit from Mr Williams staying off the Register for a further period.
Alison Bruce, Disciplinary Committee Chairman, said: "We would like to make it clear that we always find it distressing to remove clinically competent veterinary surgeons from the Register because of an irresponsible and cavalier attitude towards certification. This would not be necessary if veterinary surgeons were to follow the Twelve Principles of Certification annexed to the RCVS Guide to Professional Conduct."
The Committee then approved Mr Williams' application and directed that his name should be restored to the Register.
Vetsonic has taken over the marketing of Cavalesse, the oral nutritional supplement for horses that are prone to skin allergies, such as sweet itch.
Cavalesse contains a formulation of water-soluble vitamins and minerals, administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat. Vetsonic claims the supplement helps horses maintain a healthy skin and promotes normal immune function.
Ray Rochester, Managing Director of Vetsonic said: "It's an exciting phase in the development of Vetsonic which will see us rapidly expanding in the increasingly competitive small animal and equine market. Cavalesse is a welcome addition to our portfolio."
For further information, contact Vetsonic customer services on 01653 695333.
The module, which accounts for one hour’s CPD, is facilitated by a Boehringer Ingelheim territory manager and presented by Dr Tim Brazil BVSc, PhD, CertEM, DECEIM, MRCVS, a leading expert in equine internal medicine.
Boehringer says the presentation will help refresh veterinary professionals’ knowledge on equine lower respiratory tract disease, including Recurrent Airway Obstruction (RAO), and encourage them to feel confident and fully equipped to deal with this common respiratory scenario in practice.
During the module, attendees will be guided through two common equine respiratory cases and encouraged to discuss potential approaches to diagnosis, treatment and management in the cases he describes. The module is supported by supplementary notes which can be referred to both during and after the presentation.
Additional webinars on equine respiratory disease are also available on the Boehringer Academy website. They include: Diagnosing equine lower airway disease by Scott Pirie, Managing infectious respiratory disease by Phil Ivens, Clinical diagnostics and management of acute respiratory distress by Tim Brazil and Treatment of inflammatory airway disease by David Rendle.
To book your in-practice CPD meeting, contact your local Boehringer Ingelheim territory manager.
To view the equine respiratory disease webinars, visit www.boehringer-academy.co.uk and search for 'Inspiring CPD'.
If you're attending BEVA this September you can win a place on the CEVA-sponsored Equine Ski-PD break in January 2010, combining a couple of days of first class Continued Professional Development (CPD) with some excellent skiing in the Italian Alps.
The course runs from 13-17 January 2009 and the CPD will be spread over five sessions, equating to two-and-a-half days. Equine vets Jane Boswell, Henry Tremaine, Professor Bruce McGorum, Professor Peter Clegg and Dr Tim Brazil will cover the topics of tendonitis, wound management, ophthalmology, internal medicine and joint disease.
Skiing will be at Courmayeur, a traditional Alpine village on the Italian side of Mont Blanc, where all levels of ability, from beginners to experienced off-piste skiers, can be catered for.
To win your place, which includes flights and four nights b&b accommodation, simply visit the CEVA stand at BEVA and answer a questionnaire on Tildren®, CEVA's bisphosphonate-based treatment for equine bone disease, based on information provided via a short film loop that will be running on the stand.
For further information on equine Ski-PD contact the organisers: ben.mayes@equinevetpractice.co.uk or henry.tremaine@bristol.ac.uk
Veterinary practices are being encouraged to enter the annual Veterinary Marketing Association's (VMA) awards, which now include a practice-only category.
The annual VMA awards are intended to recognise excellence in all aspects of veterinary and animal health marketing. The Practice Marketing Award, sponsored by Pfizer, is awarded to the companion or production animal practice that demonstrates the most initiative and innovation in the marketing of its products and/or services to end users. This can involve the use of any form of activity, including advertising, websites, direct mail and media relations.
Last year's winner of this award was Kessock Equine Vets from Aberdeen, who travelled down to London to receive their award at a presentation lunch. The 2009 awards presentation ceremony takes place on Friday, 19th March at the Old Brewery in Chiswell Street, London. The meeting also presents a very good opportunity for vets to meet representatives from all the major animal health companies.
Tickets for the event cost £115+VAT for VMA/VMPA members (£150+VAT for non-members). The price includes a three-course meal (prepared by a two-star Michelin chef) with wine, a champagne reception and entertainment by a top comedian.
Further information on the awards is available on the Veterinary Marketing Association's website - http://www.vma.org.uk/. Closing date for entries is 5th February 2010.
BEVA has announced that tickets are now on sale for BEVA Congress and members who register before 4th August 2016 can benefit from big discounts.
This year, BEVA Congress is being held at the ICC in central Birmingham.
In addition to the clinical programme, tactics to achieve the elusive work life balance and the applicability of evidence based medicine are recurring themes over the three days of the event.
Five separate programmes will run concurrently in five adjacent halls, deploying a mix of traditional lectures, panel discussions and interactive forums to suit equine vets and mixed practitioners at any stage in their career. Vet nurses, farriers, equine physiotherapists and equine dental technicians can also attend specific sessions focused on their areas of expertise.
There will be daily practical sessions in the exhibition hall: Jonathan Anderson, Will Barker, Tim Barnett, Ollie Crowe, Richard Reardon, Neil Townsend and Thomas Witte will be demonstrating sinoscopy and gastroscopy techniques and delegates will have the chance to roll up their sleeves and get hands on with dead heads and digital models.
Programme highlights include a day of advanced orthopaedics in combination with the European Society of Veterinary Orthopaedics and Traumatology (ESVOT). The sessions will draw on canine and human experience, with speakers including Ian Wright from the Newmarket Equine Hospital, Peter Clegg from the University of Liverpool, Wayne McIlwraith from Colorado State University and Martin Waselau from Equine Hospital Aschheim, Germany.
There will also be career and practice development sessions exploring what you can do with your veterinary degree, how to look after your staff and how to take advantage of smartphone technology in practice. Evidence in surgery and critical appraisal tools will be explored in a series of presentations on two separate days across a wide range of conditions. Speakers will include Will Barker, Bruce McGorum, and Etienne O'Brien.
Kathy Clarke, Professor of Veterinary Anaesthesia at the Royal Veterinary College, will be giving the plenary lecture on from the difficult horse to the demanding surgeon; how effective sedation has revolutionised what is achievable in equine clinical practice. There will be a debate on the Friday with Victoria Harris chairing the promisingly divisive This house believes that lab tests are overused and abused.
There will also be comprehensive sessions on parasitology, laminitis, skin disease, anaesthesia and analgesia, colic, respiratory disease, sports injuries, standing surgery, ophthalmology, diagnostics, wounds, neurology and differentiating lameness from neurological disease, mare and foal, reproduction, dentistry, gastro intestinal disease and nutrition, cardiology and medicine.
Saturday’s vet nurse sessions will cover surgical management, emergency patients, the use of antimicrobials and adjunctive therapies. In addition, daily clinical research presentations will provide exclusive opportunities to hear about novel and exciting research projects.
There's a free BEVA Congress App with the full scientific programme and to help you manage your day. And if you are struggling for time or torn between several lectures you can use the BEVA Congress Encore Room which gives you the chance to play back missed lectures at your convenience.
For more information, visit www.beva.org.uk.
The nine-page booklet is being distributed electronically to all BEVA members, together with a guide on spotting some of the warning signs horses may display, written by equine veterinary surgeon and behaviourist Gemma Pearson.
A report commissioned by the BEVA in 2013 indicated that an equine vet could expect to sustain between seven and eight work-related injuries that impeded them from practicing, during a 30-year working life.
Data available from the Health and Safety Executive suggests that this is a very high number of injuries compared to other civilian occupations, including those working in the construction industry, prison service and the fire brigade.
The new guide has been produced ‘by horse vets for horse vets’ with BEVA members contributing their views, experiences and suggestions to early drafts.
It provides information for those handling and involved with equine veterinary care; to make workers consider the steps that they can take to make their activities as safe as reasonably possible by assessing a situation and implementing measures to limit the risk that vets and others are exposed to.
The guide also aims to challenge prevailing attitudes and culture. It outlines how to make ‘on the spot’ or ‘mental’ risk assessments and when to stop if a procedure becomes unsafe.
The guide is accompanied by an illustrated leaflet Signs of Increased Arousal Combined with a Negative Effective State. Written by Gemma Pearson, BVMS Cert AVP (EM) MRCVS who specialises in equine behaviour and learning theory, it explains signs of increased arousal including facial expressions, stance, movement and response.
David Mountford, CEO of BEVA said: "The new guidelines have been carefully developed to ensure that they are as pertinent, pragmatic and helpful as possible for vets in practice. Hopefully they will help to make the equine veterinary workplace a little safer."
The new guides can be downloaded at: https://www.beva.org.uk/workplacesafety
The full BEVA Congress programme is now live and super early bird tickets are available from 4th March, saving member delegates up to £200.
The one medicine thread will run through the medicine and orthopaedics and sports medicine streams as well as feature in the Peter Rossdale Plenary Lecture.
BEVA President Roger Smith said “There is much to learn from the human side as well as from what we do as vets.
"We have invited five human medical experts to make some comparative links with human medicine in their presentations.
"Bringing a different angle in this way will help predict what the future holds and advance what we do in the equine veterinary sphere.”
The full programme includes more than 90 hours of live and on-demand CPD covering almost every aspect of equine medicine, surgery and practice.
The first day will commence with an opening address from Olympic gold medallist Sally Gunnell during which she will share her thoughts on maximising performance.
Other highlights include:
Individual super early bird BEVA members prices are £524 for vets and £144 for vet nurses for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
Super early bird ends on Wednesday 29 May 2024.
www.bevacongress.org
5638 events were reported spontaneously, mainly by the marketing authorisation holder (61%), with the remainder largely reported by veterinary surgeons.
Of these, 5512 were reports of adverse reactions in animals: 829 concerning suspected lack of efficacy, 4638 concerning safety. The majority of reports concerned dogs (2927), cats (1426) and cattle (386).
In dogs, medicines for the control of epilepsy were most often suspected of not having performed as expected (80 reports) whilst vaccines were most commonly reported as having failed to work (71). However, the VMD points out that in many cases, vaccination failure was attributable to other causes (such as incomplete vaccination schedule).
In cats, flea spot-on products were most likely to be reported as not having worked (21). However, there are many reasons why owners may continue to see live fleas on their animal which are unrelated to product efficacy (such as reinfestation from the environment).
Notably, the majority of efficacy reports in horses (12/19) related to euthanasia products, which the report says should serve as a reminder that alternative means of euthanasia should always be available in case the chosen method does not proceed as planned.
Of the safety reports, 59.6% involved dogs, 31% cats, 4.9% horses and 3.9% rabbits. The majority concerned vaccines (1360 reports, most commonly general signs or symptoms, such as lethargy or pyrexia), parasiticides (472 reports, most commonly lethargy, emesis, inflammation/pruritus, depending on method of administration) and inflammation control (412 cases, most commonly emesis, renal insufficiency and diarrhoea, depending on the drug type).
There were 124 reports of adverse events in humans. Of those involving veterinary professionals (about a quarter):
The VMD says that reports of needle stick injuries involving vaccines with a mineral oil adjuvant are of particular concern, because they often fail to show that the injured party has received prompt and correct treatment, either because they are themselves unaware of the necessity for swift intervention, or because they do not take the product package information leaflet with them when seeking medical treatment.
Similarly, the VMD says that incidents involving injectable tilmicosin seem to be often dismissed as just a scratch, and that if you use these products, you should make sure you are fully aware of the warnings contained in the product leaflets.
To read the full report, visit: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/608968/PhV_Annual_Review_2015_v7.pdf
Richard Hepburn MRCVS has launched what is thought to be the world's first equine gastric ulcer study, designed to improve understanding and knowledge of ulceration in performance horses.
Mr Hepburn is conducting the InnerVision study of performance horses, which is being championed by the University of Liverpool, as part of his PhD.
21 appointed practices across the UK are participating in the study, and with each practice scoping between 10 and 20 animals, it will include well over 200 performance horses. Mr Hepburn said: "Gastric ulceration in sports horses is poorly understood, especially compared with racehorses. But what we do know is that it's a very important factor in the performance and well-being of many horses in training and competition."
2012 Paralympic Gold medallist Deb Criddle MBE also attended the launch event. She explained the difference that regular gastroscopy and ulcer management of Paralympic team horses had made to her success. Speaking about her Beijing ride, Pavaroti, she said: "If it weren't for the diagnosis and treatment of Pavaroti's ulcers I don't know what we'd have done. I would probably have had to withdraw him from training, so it made the difference between our partnership continuing or not".
Mr Hepburn expects a prevalence of approximately 60% and, keen to increase understanding of glandular ulceration, participants are being tasked to scope all areas of the stomach, pylorus and duodenum to ensure that every incidence of ulceration is diagnosed and recorded.
He says he is particularly eager to find out more about glandular disease, which hitherto has had little research: "Glandular disease appears to have a very different aetiology to squamous ulceration, and often presents with different signs. We also believe that prevalence of glandular ulceration is most common in sports horses."
"We hope that publication of this study will help all equine vets in their work with performance horses and the quest to prevent and manage equine ulcers," he added.
Merial is supporting the study with management assistance.
BCF Technology has launched a competition in which the person who submits the best photograph with the theme of: All in a day's work - animal imaging, will win an iPad 2.
To enter the competition, you need to post your photographs, (and tell BCF a little about the story behind the images) at www.facebook.com/bcftechnology or email them to: info@bcftechnology.com
Jason Rogers, Marketing Manager at BCF said: "We wanted to create a fun way to show just how interesting and different each days work is when imaging animals. We have made the competition open to all that work with animal imaging including our staff, dealers and vets, vet nurses, animal contractors, etc from all over the world.
"It is great to see the BCF office in the States and our international dealers also promoting the competition in their own countries, making the competition truly international. Response to the competition has been fantastic - see our facebook page to some entries for yourself."
The closing date for the competition is 30th September 2011.
For more information, visit: www.bcftechnology.com
Equistro® has produced a dust-free pelleted presentation of Secreta Pro, following requests from clients. Secreta Pro-Max® was launched to vets at BEVA Congress.
Secreta Pro is a respiratory supplement used to support the bronchial system and natural defences on a long term basis.
For more information on Secreta Pro-Max® and all Equistro products, please visit http://www.equistro.co.uk/, or contact your Vetoquinol representative.
The 2020 OV Conference will offer up to 25 hours of CPD with lectures, workshops and Q&A sessions from world-class speakers in streams covering small animals, farm animals and equines. There will also be exclusive offers from industry sponsors and online networking opportunities.
The OV Conference provides an opportunity for OVs to discuss current topics of interest and recent developments in their work. Themes this year will include notifiable diseases, biosecurity and disease control, and export certification.
In addition to the live lectures, delegates will be able to view recordings of all the sessions on-demand for three months following the conference. The CPD on offer counts towards OV revalidation qualifications with the event open to all vets, as well as animal health paraprofessionals, nurses and practice managers.
David Babington MRCVS, Business Development Director at Improve International, said: "Moving the OV Conference online has given us an opportunity to harness the technology we use regularly in all of our veterinary training to bring OVs an exceptional but affordable CPD experience.
"Our excellent speakers are looking forward to sharing the latest updates in all aspects of OV work with our delegates and to discussing the challenges ahead, particularly in the light of the COVID-19 pandemic and with the UK moving inexorably towards leaving the EU at the end of the year.
"We’re looking forward to meeting our delegates old and new online at the OV Conference in September.”
The full programme and tickets are now available from https://officialvet.com
The first 150 tickets will get an ‘Early Bird’ 25% discount from £160 to £120+ VAT using the code UK.OV.EARLYBIRD.
The National Equine Health Survey is an online snapshot survey designed to uncover common health issues in horses, directly from horse owners themselves. Results of the survey are used to build a picture of equine health and disease in the UK and define priorities for future research, training and education.
Over the past six years the survey, in partnership with the British Equine Veterinary Association, has developed to become one of the UK’s most important endemic disease monitoring initiative. The results are referenced in leading veterinary and equestrian publications and papers and are regarded as valuable benchmarks for our general knowledge of horse health.
Blue Cross Education Officer Gemma Taylor said: "These majestic police horses have taken part in our survey and we hope that they will encourage others to follow suit and be ambassadors for horse welfare.
"The more data we can collect from the National Equine Health Survey the more robust our results will be, helping us to steer equine awareness, education and research to keep our nation’s horses healthier."
Last year survey records were returned for almost 17,000 horses, ponies, donkeys and mules and the six most notable disease syndromes identified.
To take part in the National Equine Health Survey, visit: www.bluecross.org.uk/NEHS
To find out more about Blue Cross’s rescue and rehoming work with horses and ponies visit bluecross.org.uk
Animal Health and Veterinary Laboratories Agency (AHVLA) has announced the formation of a new independent advisory group to recommend a future delivery model for veterinary surveillance in England and Wales.
The Advisory Group will be chaired by Dirk Pfeiffer, Professor of Veterinary Epidemiology at the Royal Veterinary College. According to the AHVLA, it will include representatives from government, the veterinary profession and the livestock farming and private laboratory industries and is being created so all those with an interest in veterinary surveillance can shape a future model and ensure that all issues are thoroughly considered.
Veterinary surveillance seeks to identify new or re-emerging threats to our livestock population and to public health. It involves a partnership approach between livestock keepers, private veterinary surgeons, the Scottish Agricultural College, industry bodies and AHVLA in order to effectively gather and assess intelligence.
AHVLA is seeking to identify ways to undertake veterinary surveillance both more effectively and at an affordable cost to the taxpayer. Work in this area has been on-going since 2010, and the merger of the former Animal Health and Veterinary Laboratories Agency (VLA) has created opportunities to review how veterinary surveillance can best be delivered.
The new model will aim to address capacity imbalances in the current service where provision sometimes outstrips demand. The independent advisory group are also expected to recommend how better and closer working methods across the partners can make the surveillance stronger as well as more cost effective.
Surveillance has historically been based on in-depth investigation of disease incidents with an emphasis on post mortem examinations carried out at AHVLA's regional laboratories. This system is a key element in the government's risk-based approach to the management of animal disease related threats.
AHVLA says that the current model, although successful in identifying diseases in the past, can be improved upon. A recent internal AHVLA report identified viable options for achieving better surveillance at the same or lower cost by, for example, exploring moving towards risk and intelligence based surveillance and improving the value added by working more closely in partnership with vets and their farmer clients and other sources of intelligence data.
In mid-January 2012, AHVLA will also be publishing, and publicising, an online survey aimed at individual veterinary practioners and livestock keepers. The survey will seek individual opinions on the inputs, mechanisms, outputs and value of surveillance in England and Wales Work is expected to run until spring 2012, following which recommendations on a way forward will be made.
Carl Padgett, President of the BVA, said: “Veterinary surveillance is an essential component in our animal health, public health, food security, and international trade work.
“The emergence of Schmallenberg virus in ruminants in northern Europe demonstrates the current value and ongoing need for a robust surveillance system to work both nationally and internationally.
“The BVA welcomes the establishment of the advisory group and particularly the wide range of veterinary expertise and experience that is represented on the group. It is important that views from both veterinary practitioners and veterinary scientists are fed into this review.
“While we understand that AHVLA and Defra must ensure value for money from the surveillance network, any future model must be shaped by good surveillance strategies, not the need to cut costs.
“We urge all practitioners in England and Wales to contribute to the discussions by completing the online survey.
“We look forward to engaging with the advisory group as it carries out the review and beyond.”
A research project funded by The Horse Trust has made important discoveries about how two peptides regulate the inflammatory response in horses. This knowledge could help with the development of improved anti-inflammatory drugs, which are used to treat a wide range of conditions in horses.
The research project was led by Professor Fiona Cunningham at the Royal Veterinary College in Hertfordshire and Dr Karen Rickards at the Donkey Sanctuary in Sidmouth, assisted by Dr Andrew Brooks at the RVC, and by Dr Kirstie Pickles, now at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Inflammation is associated with a wide range of equine diseases, including recurrent airway obstruction, laminitis and sweet itch. Anti-inflammatory drugs, such as glucocorticosteroids, mainly work by blocking the formation and/or actions of compounds produced in the horse's body that cause inflammatory responses. However, these drugs are not always effective and can have unwanted side effects.
This research, funded by The Horse Trust, aimed to find out more about two naturally-occurring peptides - chains of amino acids that are shorter than proteins - known as annexin-1 and CXCL8. Both have been shown to affect the inflammatory response but little research has been done on their effects in horses. In the long term, knowing more about these compounds could help in the development of new anti-inflammatory drugs with fewer side effects.
During inflammation, neutrophils (a type of white blood cell) stick to the cells lining blood vessels and migrate into inflamed tissue, where they ingest and break down harmful agents. Using techniques that mimic these events, CXCL8 was found to cause adherence and migration of horse neutrophils. However, when it was used in combination with another pro-inflammatory substance, neutrophil migration and adherence were markedly decreased. This suggests that attempts to reduce inflammation by blocking the actions of CXCL8 might not be as beneficial as had been thought.
At the start of the project, the researchers had no information about horse annexin-1, other than its gene sequence, so their first step was to develop a method to detect the peptide in white blood cells. They established that it was present and, as horse annexin-1 has not yet been synthesised, they used a synthetic peptide derived from annexin-1, Ac2-26, to look at the effects on horse neutrophils.
They found that Ac2-26 decreased neutrophil adherence and migration in response to other pro-inflammatory compounds, although at high concentrations the peptide itself caused some cell activation, thereby increasing inflammation. They also found that dexamethasone (a glucocorticosteroid) increased the levels of annexin-1 in cells, indicating that, as in humans, this class of drugs is likely to act in part through the formation of annexin-1.
These findings suggest that the use of compounds which mimic the actions of annexin-1 may have limitations as anti-inflammatory drugs. As glucocorticosteroids partly work by forming annexin-1, further research is needed in order to find out how annexin-1 will act in the horse's body and establish how its formation contributes to the beneficial effects of these drugs.
Professor Cunningham said: "This Horse Trust-funded research has resulted in some very interesting findings about how inflammatory cells are regulated in horses. The receptors that annexin-1 and CXCL8 act upon could be targets for new equine inflammatory drugs, but more research is needed first to fully understand their actions and how they produce these effects."
The team's research has been accepted for publication by the journal Veterinary Immunology & Immunopathology.